Category: St. Jude MedicalSyndicate content

UPDATE: CardioMEMS CEO on FDA's Champion ruling

December 9, 2011 by MassDevice staff

An FDA advisory panel fails to confirm that the benefits outweigh the risks of a CardioMEMS implantable heart pressure monitor, casting a shadow on St. Jude Medical's potential $375 million buyout.

CardioMEMS

UPDATED Dec. 9, 2011, with comments from CardioMEMS CEO Dr. Jay Yadav, trial results

FDA panel thumbs down on CardioMEMS implantable heart monitor

December 9, 2011 by MassDevice staff

An FDA advisory panel fails to confirm that the benefits outweigh the risks of a CardioMEMS implantable heart pressure monitor, casting a shadow on St. Jude Medical's potential $375 million buyout.

CardioMEMS
St. Jude Medical

An FDA advisory panel decided that CardioMEMS failed to prove that its wireless, implantable heart monitor's benefits outweigh its risks, casting a shadow on a potential $375 million acquisition by St. Jude Medical (NYSE:STJ) – which already owns nearly a fifth of CardioMEMS.

Med-tech stocks rebound after Medicare jolt | Wall Street Beat

December 7, 2011 by MassDevice staff

Shares of medical device-making companies recover from the slide triggered last week by a Medicare pilot program in 11 states that will ask docs for up-front proof that procedures are necessary; also, Boston Scientific a "fast follower?"; do med-tech stocks pass the Buffett Test?; the latest on the scandal at Olympus; and analysts' ups & downs.

MassDevice.com Wall Street Beat

Wall Street investors rebounded from the jolt delivered by the Centers for Medicare & Medicaid Services last week, regaining most of the value lost after the agency announced stiffer rules for its coverage of some medical procedures.

The new pre-reimbursement review program will ask doctors to provide up-front justification for certain medical equipment and types of claims. Set to launch in 11 states next month, it will flip the reimbursement system from the agency's existing "pay-and-chase" method of looking for improper payments after they've already been made.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Med-tech stocks rebound after Medicare jolt

December 7, 2011 by MassDevice staff

Shares of medical device-making companies recover from the slide triggered last week by a Medicare pilot program in 11 states that will ask docs for up-front proof that procedures are necessary.

MassDevice.com Wall Street Beat

Wall Street investors rebounded from the jolt delivered by the Centers for Medicare & Medicaid Services last week, regaining most of the value lost after the agency announced stiffer rules for its coverage of some medical procedures.

The new pre-reimbursement review program will ask doctors to provide up-front justification for certain medical equipment and types of claims. Set to launch in 11 states next month, it will flip the reimbursement system from the agency's existing "pay-and-chase" method of looking for improper payments after they've already been made.

MassDevice.com +7 | MDT to cut $1.2B, Acquisition chatter for SNN, Olympus's fire sale, FDA chemist, Bovie's COO, FDA's artificial pancreas guidance and St. Judes' Quantra win

December 3, 2011 by MassDevice staff

The top seven medical device stories for the week of November 28, 2011.

Plus Seven

Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.

Abiomed hits 52-week high | Wall Street Beat

December 1, 2011 by MassDevice staff

Abiomed shares hit a 52-week high yesterday as it announces new data from a study of its flagship Impella heart pump in treating complex cases; also, options market bearish on Medtronic; November's winners and losers; and analysts' ups and downs.

MassDevice.com Wall Street Beat

Abiomed (NSDQ:ABMD) shares hit $20.25 apiece yesterday, their highest mark in 52 weeks, as the company touted more positive study results for its flagship Impella heart pump.

ABMD shares closed yesterday at $20.14, up 6.2 percent on a day of widespread gains on Wall Street. The Dow Jones Industrial Average gained 4.2 percent yesterday, the S&P 500 closed up 4.3 percent and the Dow Jones medical device index rose 4.8 percent.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

MassDevice.com +3 | Bovie questions COO's credentials, St. Jude announces FDA win amid Riata lead concerns and Histogen wins patent battle against SkinMedica

November 30, 2011 by MassDevice staff

The top three medical device stories for November 30, 2011.

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com's coverage highlights our three biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else today, make sure you're still in the know with MassDevice +3.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp